D9641
Deoxygalactonojirimycin hydrochloride
powder or solid, ≥98% (HPLC)
Synonym(s):
1,5-Dideoxy-1,5-imino-D-galactitol, Migalastat
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C6H13NO4 · HCl
CAS Number:
Molecular Weight:
199.63
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.32
Recommended Products
Product Name
Deoxygalactonojirimycin hydrochloride,
biological source
synthetic (organic)
Quality Level
Assay
≥98% (HPLC)
form
powder or solid
solubility
water: soluble 1 mg/mL
storage temp.
−20°C
SMILES string
Cl.OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O
InChI
1S/C6H13NO4.ClH/c8-2-3-5(10)6(11)4(9)1-7-3;/h3-11H,1-2H2;1H/t3-,4+,5+,6-;/m1./s1
InChI key
ZJIHMALTJRDNQI-OLALXQGDSA-N
Application
Deoxygalactonojirimycin hydrochloride has been used as an α-galactosidase A inhibitor to assess the enzymatic activity of α-galactosidase A. It has also been used as an α-galactosidase A inhibitor to study its effects on the mRNA levels in human embryonic kidney (HEK) cells and hippocampal neurons.
Biochem/physiol Actions
Deoxygalactonojirimycin hydrochloride is an inhibitor of α-galactosidase A. Deoxygalactonojirimycin exhibits therapeutic effects against Fabry disease.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Paulsen, H., et al.
Chemische Berichte, 113, 2601-2601 (1980)
Libia Catalina Salinas Castellanos et al.
Neurochemistry international, 140, 104824-104824 (2020-08-26)
Neuropathic pain is one of the key features of the classical phenotype of Fabry disease (FD). Acid sensing ion channels (ASICs) are H+-gated cation channels, which belong to the epithelial sodium channel/DeGenerin superfamily, sensitive to the diuretic drug Amiloride. Molecular
Antonino Tuttolomondo et al.
Oncotarget, 8(37), 61415-61424 (2017-10-06)
Anderson-Fabry disease (AFD) is an inborn lysosomal enzymopathy resulting from the deficient or absent activity of the lysosomal exogalactohydrolase, α-galactosidase A. This deficiency, results in the altered metabolism of glycosphingolipids which leads to their accumulation in lysosomes, thus to cellular
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service